Nippon Shinyaku Co., Ltd. Overview
Pro stress-test →Nippon Shinyaku is a Tokyo Stock Exchange-listed Japanese pharmaceutical and functional food company founded in 1911 and headquartered in Kyoto. The company manufactures and sells pharmaceuticals targeting urology, hematology, rare diseases, and gynecology, alongside functional food ingredients and supplements, generating approximately ¥160 billion in annual revenue.
Strategic Profile
Pro stress-test →Nippon Shinyaku maintains competitive advantage through specialized pharmaceutical portfolio in underserved therapeutic areas and strategic partnerships for rare disease treatments (ATSN-10 for Leber congenital amaurosis and RGX-121 for mucopolysaccharidosis in clinical trials). The company is expanding internationally with recent European rights acquisitions for Duchenne muscular dystrophy therapy, demonstrating a pivot toward high-growth rare disease and specialty pharmaceutical segments.
Competitive Landscape
Pro stress-test →Nippon Shinyaku competes within specialized pharmaceutical niches rather than broadly against mega-cap pharma. Primary domestic competitors include Tsumura (herbal medicines) and regional Japanese pharma firms. International competition in rare diseases/specialty pharma includes Roche, Novartis, and Biogen, though Nippon Shinyaku's niche focus and partnerships provide differentiation in underserved therapeutic areas.
Industry Context
Nippon Shinyaku Co., Ltd. operates in Pharmaceuticals & Functional Foods.
Key facts
Founded: 1911 · Headquarters: Kyoto, Japan · Employees: 2,240 · Revenue: ¥160.2B · Market cap: ¥212.4B